Cell Biosciences Announces US Patent Issuance

SANTA CLARA, California, December 14, 2010 - Cell Biosciences, Inc. today announced the issuance of Patent No.
7,846,676 for "Methods and Devices for Analyte Detection" by the United
States Patent and Trademark Office.

The patent represents a key element of intellectual property related to
NanoPro assay technology. It is one of several within a family directed
towards the detection of specific proteins in complex biological samples.
NanoPro assay technology is used by premier researchers in the fields of
cancer research, stem cell biology, diabetes and drug development to
characterize proteins in extremely small and precious samples, enabling
accelerated development of new therapeutics and identification of new
prognostic and diagnostic disease biomarkers.

"The NanoPro platform represents a transformational approach to protein
characterization," commented Bob Gavin, Vice President of Product Development
at Cell Biosciences. "The platform's ability to study proteins in extremely
small samples has led to its adoption by leading research institutions and
drug development companies worldwide. We look forward to continuing the
delivery of innovative products based on this technology."

About Cell Biosciences

Our company develops instrumentation systems, software and assay products
that drive discoveries in fields ranging from fundamental protein research to
biomarker discovery and personalized medicine. With an installed base of over
10,000 systems, our customers include leading research institutions and
pharmaceutical/biotechnology companies worldwide. Cell Biosciences is
headquartered in Santa Clara, California, with direct sales and service in
North America, Europe and Asia. For more information, visit
www.cellbiosciences.com.

Trent Basarsky, Vice President of Corporate Development of Cell Biosciences, Inc., +1-408-510-5547, tbasarsky at cellbiosciences.com